JP2013530957A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013530957A5 JP2013530957A5 JP2013513348A JP2013513348A JP2013530957A5 JP 2013530957 A5 JP2013530957 A5 JP 2013530957A5 JP 2013513348 A JP2013513348 A JP 2013513348A JP 2013513348 A JP2013513348 A JP 2013513348A JP 2013530957 A5 JP2013530957 A5 JP 2013530957A5
- Authority
- JP
- Japan
- Prior art keywords
- methyl
- piperazin
- benzamide
- cyclohexyl
- difluoro
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 claims description 626
- -1 2-cyanophenyl Chemical group 0.000 claims description 133
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 94
- 150000001875 compounds Chemical class 0.000 claims description 81
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 claims description 66
- 125000000217 alkyl group Chemical group 0.000 claims description 54
- 229910052739 hydrogen Inorganic materials 0.000 claims description 50
- 229910052757 nitrogen Inorganic materials 0.000 claims description 47
- PAMCRRDMORMCSM-UHFFFAOYSA-N n-(trifluoromethyl)benzamide Chemical compound FC(F)(F)NC(=O)C1=CC=CC=C1 PAMCRRDMORMCSM-UHFFFAOYSA-N 0.000 claims description 44
- 239000001257 hydrogen Substances 0.000 claims description 40
- 125000001424 substituent group Chemical group 0.000 claims description 38
- 229910052799 carbon Inorganic materials 0.000 claims description 35
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical group N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 34
- 125000001072 heteroaryl group Chemical group 0.000 claims description 33
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 32
- 150000002367 halogens Chemical class 0.000 claims description 28
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 27
- 125000003118 aryl group Chemical group 0.000 claims description 26
- 229910052736 halogen Inorganic materials 0.000 claims description 26
- 229910052794 bromium Inorganic materials 0.000 claims description 20
- 229910052801 chlorine Inorganic materials 0.000 claims description 20
- 229910052731 fluorine Inorganic materials 0.000 claims description 20
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 20
- 125000000623 heterocyclic group Chemical group 0.000 claims description 17
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims description 16
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims description 16
- 150000002431 hydrogen Chemical class 0.000 claims description 16
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 claims description 14
- 229910052805 deuterium Inorganic materials 0.000 claims description 14
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 14
- 150000001721 carbon Chemical group 0.000 claims description 12
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 12
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 11
- 125000005842 heteroatom Chemical group 0.000 claims description 11
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 10
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 10
- 229910052760 oxygen Inorganic materials 0.000 claims description 10
- 239000001301 oxygen Substances 0.000 claims description 10
- 229910052717 sulfur Chemical group 0.000 claims description 10
- 239000011593 sulfur Chemical group 0.000 claims description 10
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 9
- TURTXUSSYAAWDU-UHFFFAOYSA-N 2-chloro-n-[1-[3,3-difluoro-1-[4-(1-methyltriazol-4-yl)sulfonylpiperazin-1-yl]cyclopentyl]ethyl]-4-fluorobenzamide Chemical compound C1CC(F)(F)CC1(N1CCN(CC1)S(=O)(=O)C=1N=NN(C)C=1)C(C)NC(=O)C1=CC=C(F)C=C1Cl TURTXUSSYAAWDU-UHFFFAOYSA-N 0.000 claims description 8
- KZMAEPZALJYLFZ-UHFFFAOYSA-N 2-chloro-n-[1-[4,4-difluoro-1-[4-(1-methyltriazol-4-yl)sulfonylpiperazin-1-yl]cyclohexyl]ethyl]-4-fluorobenzamide Chemical compound C1CC(F)(F)CCC1(N1CCN(CC1)S(=O)(=O)C=1N=NN(C)C=1)C(C)NC(=O)C1=CC=C(F)C=C1Cl KZMAEPZALJYLFZ-UHFFFAOYSA-N 0.000 claims description 8
- AUGUDOWJZSIKTA-UHFFFAOYSA-N 2-chloro-n-[1-[4,4-difluoro-1-[4-(2-hydroxypropylsulfonyl)piperazin-1-yl]cyclohexyl]ethyl]-4-(trifluoromethyl)benzamide Chemical compound C1CN(S(=O)(=O)CC(O)C)CCN1C1(C(C)NC(=O)C=2C(=CC(=CC=2)C(F)(F)F)Cl)CCC(F)(F)CC1 AUGUDOWJZSIKTA-UHFFFAOYSA-N 0.000 claims description 8
- ZVZJHYTZKLHFBN-UHFFFAOYSA-N 2-chloro-n-[1-[4,4-difluoro-1-[4-(2-hydroxypropylsulfonyl)piperazin-1-yl]cyclohexyl]ethyl]-4-fluorobenzamide Chemical compound C1CN(S(=O)(=O)CC(O)C)CCN1C1(C(C)NC(=O)C=2C(=CC(F)=CC=2)Cl)CCC(F)(F)CC1 ZVZJHYTZKLHFBN-UHFFFAOYSA-N 0.000 claims description 8
- HFXBCPUSRICANI-UHFFFAOYSA-N 2-chloro-n-[[3,3-difluoro-1-[4-(1-methyltriazol-4-yl)sulfonylpiperazin-1-yl]cyclopentyl]methyl]-4-fluorobenzamide Chemical compound N1=NN(C)C=C1S(=O)(=O)N1CCN(C2(CNC(=O)C=3C(=CC(F)=CC=3)Cl)CC(F)(F)CC2)CC1 HFXBCPUSRICANI-UHFFFAOYSA-N 0.000 claims description 8
- DCWUQWDXVQPWFD-UHFFFAOYSA-N 2-chloro-n-[[4,4-difluoro-1-[1-(1-methyltriazol-4-yl)sulfonylpiperidin-4-yl]cyclohexyl]methyl]-4-fluorobenzamide Chemical compound N1=NN(C)C=C1S(=O)(=O)N1CCC(C2(CNC(=O)C=3C(=CC(F)=CC=3)Cl)CCC(F)(F)CC2)CC1 DCWUQWDXVQPWFD-UHFFFAOYSA-N 0.000 claims description 8
- WVFMVRCDAYHCFP-UHFFFAOYSA-N 2-chloro-n-[[4,4-difluoro-1-[4-(1-methyltriazol-4-yl)sulfonylpiperazin-1-yl]cyclohexyl]methyl]-4-fluorobenzamide Chemical compound N1=NN(C)C=C1S(=O)(=O)N1CCN(C2(CNC(=O)C=3C(=CC(F)=CC=3)Cl)CCC(F)(F)CC2)CC1 WVFMVRCDAYHCFP-UHFFFAOYSA-N 0.000 claims description 8
- SAJCDXSXUPJGDH-UHFFFAOYSA-N 2-chloro-n-[[4,4-difluoro-1-[4-(2-hydroxypropylsulfonyl)piperazin-1-yl]cyclohexyl]methyl]-4-fluorobenzamide Chemical compound C1CN(S(=O)(=O)CC(O)C)CCN1C1(CNC(=O)C=2C(=CC(F)=CC=2)Cl)CCC(F)(F)CC1 SAJCDXSXUPJGDH-UHFFFAOYSA-N 0.000 claims description 8
- 125000002816 methylsulfanyl group Chemical group [H]C([H])([H])S[*] 0.000 claims description 8
- DZZKZKMVWFISEJ-UHFFFAOYSA-N n-(trifluoromethoxy)benzamide Chemical compound FC(F)(F)ONC(=O)C1=CC=CC=C1 DZZKZKMVWFISEJ-UHFFFAOYSA-N 0.000 claims description 8
- QXQAHHNEFOJTND-UHFFFAOYSA-N n-[1-[4,4-difluoro-1-[4-(2-hydroxypropylsulfonyl)piperazin-1-yl]cyclohexyl]ethyl]-2,4-bis(trifluoromethyl)benzamide Chemical compound C1CN(S(=O)(=O)CC(O)C)CCN1C1(C(C)NC(=O)C=2C(=CC(=CC=2)C(F)(F)F)C(F)(F)F)CCC(F)(F)CC1 QXQAHHNEFOJTND-UHFFFAOYSA-N 0.000 claims description 8
- WXQQATYKMOKZNA-UHFFFAOYSA-N n-[[4,4-difluoro-1-[4-(2-hydroxypropylsulfonyl)piperazin-1-yl]cyclohexyl]methyl]-2,4-bis(trifluoromethyl)benzamide Chemical compound C1CN(S(=O)(=O)CC(O)C)CCN1C1(CNC(=O)C=2C(=CC(=CC=2)C(F)(F)F)C(F)(F)F)CCC(F)(F)CC1 WXQQATYKMOKZNA-UHFFFAOYSA-N 0.000 claims description 8
- 150000003839 salts Chemical class 0.000 claims description 8
- SVSYRJUZUMWRMS-UHFFFAOYSA-N 2,4-dichloro-n-[1-[4,4-difluoro-1-[4-(2-hydroxypropylsulfonyl)piperazin-1-yl]cyclohexyl]ethyl]benzamide Chemical compound C1CN(S(=O)(=O)CC(O)C)CCN1C1(C(C)NC(=O)C=2C(=CC(Cl)=CC=2)Cl)CCC(F)(F)CC1 SVSYRJUZUMWRMS-UHFFFAOYSA-N 0.000 claims description 7
- CMCKVSNJYGAWMX-UHFFFAOYSA-N 2,4-dichloro-n-[[4,4-difluoro-1-[4-(2-hydroxypropylsulfonyl)piperazin-1-yl]cyclohexyl]methyl]benzamide Chemical compound C1CN(S(=O)(=O)CC(O)C)CCN1C1(CNC(=O)C=2C(=CC(Cl)=CC=2)Cl)CCC(F)(F)CC1 CMCKVSNJYGAWMX-UHFFFAOYSA-N 0.000 claims description 7
- NNSLNEKLYAQUJI-UHFFFAOYSA-N 2-chloro-n-[[4,4-difluoro-1-[4-(2-hydroxypropylsulfonyl)piperazin-1-yl]cyclohexyl]methyl]-4-(trifluoromethyl)benzamide Chemical compound C1CN(S(=O)(=O)CC(O)C)CCN1C1(CNC(=O)C=2C(=CC(=CC=2)C(F)(F)F)Cl)CCC(F)(F)CC1 NNSLNEKLYAQUJI-UHFFFAOYSA-N 0.000 claims description 7
- 125000004194 piperazin-1-yl group Chemical group [H]N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 claims description 7
- 125000001359 1,2,3-triazol-4-yl group Chemical group [H]N1N=NC([*])=C1[H] 0.000 claims description 6
- QCIDEYLDAGNHRM-UHFFFAOYSA-N 2-chloro-n-[[4,4-difluoro-1-[4-(1-methylimidazol-4-yl)sulfonylpiperazin-1-yl]cyclohexyl]methyl]-4-fluorobenzamide Chemical compound CN1C=NC(S(=O)(=O)N2CCN(CC2)C2(CNC(=O)C=3C(=CC(F)=CC=3)Cl)CCC(F)(F)CC2)=C1 QCIDEYLDAGNHRM-UHFFFAOYSA-N 0.000 claims description 6
- 125000002618 bicyclic heterocycle group Chemical group 0.000 claims description 6
- 125000002950 monocyclic group Chemical group 0.000 claims description 6
- FGMUHFCARDYHEJ-UHFFFAOYSA-N n-[[4,4-difluoro-1-(4-propylsulfonylpiperazin-1-yl)cyclohexyl]methyl]-2,6-difluorobenzamide Chemical compound C1CN(S(=O)(=O)CCC)CCN1C1(CNC(=O)C=2C(=CC=CC=2F)F)CCC(F)(F)CC1 FGMUHFCARDYHEJ-UHFFFAOYSA-N 0.000 claims description 6
- GKWBCTOARGYUIM-UHFFFAOYSA-N n-[[4,4-difluoro-1-[4-(1-methylimidazol-4-yl)sulfonylpiperazin-1-yl]cyclohexyl]methyl]-2,4-difluorobenzamide Chemical compound CN1C=NC(S(=O)(=O)N2CCN(CC2)C2(CNC(=O)C=3C(=CC(F)=CC=3)F)CCC(F)(F)CC2)=C1 GKWBCTOARGYUIM-UHFFFAOYSA-N 0.000 claims description 6
- AUEBMLQTZVKCHZ-UHFFFAOYSA-N n-[[4,4-difluoro-1-[4-(1-methylimidazol-4-yl)sulfonylpiperazin-1-yl]cyclohexyl]methyl]-2,6-difluorobenzamide Chemical compound CN1C=NC(S(=O)(=O)N2CCN(CC2)C2(CNC(=O)C=3C(=CC=CC=3F)F)CCC(F)(F)CC2)=C1 AUEBMLQTZVKCHZ-UHFFFAOYSA-N 0.000 claims description 6
- IDGULWSAVILSTK-UHFFFAOYSA-N n-[[4,4-difluoro-1-[4-(1-methyltriazol-4-yl)sulfonylpiperazin-1-yl]cyclohexyl]methyl]-2,6-difluorobenzamide Chemical compound N1=NN(C)C=C1S(=O)(=O)N1CCN(C2(CNC(=O)C=3C(=CC=CC=3F)F)CCC(F)(F)CC2)CC1 IDGULWSAVILSTK-UHFFFAOYSA-N 0.000 claims description 6
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 6
- 229920006395 saturated elastomer Polymers 0.000 claims description 6
- 239000012453 solvate Substances 0.000 claims description 6
- 125000000446 sulfanediyl group Chemical group *S* 0.000 claims description 6
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 5
- VJLVVCSODSTMLL-UHFFFAOYSA-N 2,4-dichloro-n-[[1-[4-(cyclopropylmethylsulfonyl)piperazin-1-yl]cyclohexyl]methyl]benzamide Chemical compound ClC1=CC(Cl)=CC=C1C(=O)NCC1(N2CCN(CC2)S(=O)(=O)CC2CC2)CCCCC1 VJLVVCSODSTMLL-UHFFFAOYSA-N 0.000 claims description 4
- FWLOIOZRFHTSGQ-UHFFFAOYSA-N 2,4-dichloro-n-[[4,4-difluoro-1-(4-propylsulfonylpiperazin-1-yl)cyclohexyl]methyl]-6-fluorobenzamide Chemical compound C1CN(S(=O)(=O)CCC)CCN1C1(CNC(=O)C=2C(=CC(Cl)=CC=2F)Cl)CCC(F)(F)CC1 FWLOIOZRFHTSGQ-UHFFFAOYSA-N 0.000 claims description 4
- ALDDUEZQMUCKST-UHFFFAOYSA-N 2,4-dichloro-n-[[4,4-difluoro-1-[4-(1-methyltriazol-4-yl)sulfonylpiperazin-1-yl]cyclohexyl]methyl]-5-fluorobenzamide Chemical compound N1=NN(C)C=C1S(=O)(=O)N1CCN(C2(CNC(=O)C=3C(=CC(Cl)=C(F)C=3)Cl)CCC(F)(F)CC2)CC1 ALDDUEZQMUCKST-UHFFFAOYSA-N 0.000 claims description 4
- PIEOCXSJAKIRDH-UHFFFAOYSA-N 2,4-dichloro-n-[[4,4-difluoro-1-[4-(1-methyltriazol-4-yl)sulfonylpiperazin-1-yl]cyclohexyl]methyl]-6-fluorobenzamide Chemical compound N1=NN(C)C=C1S(=O)(=O)N1CCN(C2(CNC(=O)C=3C(=CC(Cl)=CC=3F)Cl)CCC(F)(F)CC2)CC1 PIEOCXSJAKIRDH-UHFFFAOYSA-N 0.000 claims description 4
- XASFTYNOHQXSBP-UHFFFAOYSA-N 2-(difluoromethoxy)-n-[[4,4-difluoro-1-(4-propylsulfonylpiperazin-1-yl)cyclohexyl]methyl]-6-fluorobenzamide Chemical compound C1CN(S(=O)(=O)CCC)CCN1C1(CNC(=O)C=2C(=CC=CC=2F)OC(F)F)CCC(F)(F)CC1 XASFTYNOHQXSBP-UHFFFAOYSA-N 0.000 claims description 4
- DESJHZMZICSFLF-UHFFFAOYSA-N 2-chloro-n-[[4,4-difluoro-1-(4-propylsulfonylpiperazin-1-yl)cyclohexyl]methyl]-4-fluorobenzamide Chemical compound C1CN(S(=O)(=O)CCC)CCN1C1(CNC(=O)C=2C(=CC(F)=CC=2)Cl)CCC(F)(F)CC1 DESJHZMZICSFLF-UHFFFAOYSA-N 0.000 claims description 4
- PVRPGBYPVMWMJP-UHFFFAOYSA-N 2-chloro-n-[[4,4-difluoro-1-(4-propylsulfonylpiperazin-1-yl)cyclohexyl]methyl]-6-fluorobenzamide Chemical compound C1CN(S(=O)(=O)CCC)CCN1C1(CNC(=O)C=2C(=CC=CC=2F)Cl)CCC(F)(F)CC1 PVRPGBYPVMWMJP-UHFFFAOYSA-N 0.000 claims description 4
- HYGYDYZYVIJRAT-UHFFFAOYSA-N 2-chloro-n-[[4,4-difluoro-1-(4-propylsulfonylpiperazin-1-yl)cyclohexyl]methyl]-6-methylbenzamide Chemical compound C1CN(S(=O)(=O)CCC)CCN1C1(CNC(=O)C=2C(=CC=CC=2C)Cl)CCC(F)(F)CC1 HYGYDYZYVIJRAT-UHFFFAOYSA-N 0.000 claims description 4
- BGYGHCORXUALDD-UHFFFAOYSA-N 2-chloro-n-[[4,4-difluoro-1-[4-(1-fluoropropylsulfonyl)piperazin-1-yl]cyclohexyl]methyl]-4-(trifluoromethyl)benzamide Chemical compound C1CN(S(=O)(=O)C(F)CC)CCN1C1(CNC(=O)C=2C(=CC(=CC=2)C(F)(F)F)Cl)CCC(F)(F)CC1 BGYGHCORXUALDD-UHFFFAOYSA-N 0.000 claims description 4
- IIJNRBXCHDFXSK-UHFFFAOYSA-N 2-chloro-n-[[4,4-difluoro-1-[4-(1-methylimidazol-4-yl)sulfonylpiperazin-1-yl]cyclohexyl]methyl]-6-fluorobenzamide Chemical compound CN1C=NC(S(=O)(=O)N2CCN(CC2)C2(CNC(=O)C=3C(=CC=CC=3F)Cl)CCC(F)(F)CC2)=C1 IIJNRBXCHDFXSK-UHFFFAOYSA-N 0.000 claims description 4
- NNXNSPNPDLOLRG-UHFFFAOYSA-N 2-chloro-n-[[4,4-difluoro-1-[4-(1-methylimidazol-4-yl)sulfonylpiperazin-1-yl]cyclohexyl]methyl]-6-methoxybenzamide Chemical compound COC1=CC=CC(Cl)=C1C(=O)NCC1(N2CCN(CC2)S(=O)(=O)C=2N=CN(C)C=2)CCC(F)(F)CC1 NNXNSPNPDLOLRG-UHFFFAOYSA-N 0.000 claims description 4
- YEZPFCRVALSCAQ-UHFFFAOYSA-N 2-chloro-n-[[4,4-difluoro-1-[4-(1-methylimidazol-4-yl)sulfonylpiperazin-1-yl]cyclohexyl]methyl]-6-methylbenzamide Chemical compound CC1=CC=CC(Cl)=C1C(=O)NCC1(N2CCN(CC2)S(=O)(=O)C=2N=CN(C)C=2)CCC(F)(F)CC1 YEZPFCRVALSCAQ-UHFFFAOYSA-N 0.000 claims description 4
- QWHQQIRSFCCJOZ-UHFFFAOYSA-N 2-chloro-n-[[4,4-difluoro-1-[4-(1-methyltriazol-4-yl)sulfonylpiperazin-1-yl]cyclohexyl]methyl]-3-fluoro-4-methylbenzamide Chemical compound ClC1=C(F)C(C)=CC=C1C(=O)NCC1(N2CCN(CC2)S(=O)(=O)C=2N=NN(C)C=2)CCC(F)(F)CC1 QWHQQIRSFCCJOZ-UHFFFAOYSA-N 0.000 claims description 4
- AWTLKEUDKQJATH-UHFFFAOYSA-N 2-chloro-n-[[4,4-difluoro-1-[4-(1-methyltriazol-4-yl)sulfonylpiperazin-1-yl]cyclohexyl]methyl]-4,5-difluorobenzamide Chemical compound N1=NN(C)C=C1S(=O)(=O)N1CCN(C2(CNC(=O)C=3C(=CC(F)=C(F)C=3)Cl)CCC(F)(F)CC2)CC1 AWTLKEUDKQJATH-UHFFFAOYSA-N 0.000 claims description 4
- RIXBTGOYSZHJIC-UHFFFAOYSA-N 4-chloro-n-[[4,4-difluoro-1-(4-propylsulfonylpiperazin-1-yl)cyclohexyl]methyl]-2,6-difluorobenzamide Chemical compound C1CN(S(=O)(=O)CCC)CCN1C1(CNC(=O)C=2C(=CC(Cl)=CC=2F)F)CCC(F)(F)CC1 RIXBTGOYSZHJIC-UHFFFAOYSA-N 0.000 claims description 4
- GFJHJGBECCURJV-UHFFFAOYSA-N 4-chloro-n-[[4,4-difluoro-1-(4-propylsulfonylpiperazin-1-yl)cyclohexyl]methyl]-2,6-dimethylbenzamide Chemical compound C1CN(S(=O)(=O)CCC)CCN1C1(CNC(=O)C=2C(=CC(Cl)=CC=2C)C)CCC(F)(F)CC1 GFJHJGBECCURJV-UHFFFAOYSA-N 0.000 claims description 4
- YKOUJOAFGPOWTC-UHFFFAOYSA-N 4-chloro-n-[[4,4-difluoro-1-(4-propylsulfonylpiperazin-1-yl)cyclohexyl]methyl]-2-fluorobenzamide Chemical compound C1CN(S(=O)(=O)CCC)CCN1C1(CNC(=O)C=2C(=CC(Cl)=CC=2)F)CCC(F)(F)CC1 YKOUJOAFGPOWTC-UHFFFAOYSA-N 0.000 claims description 4
- FKLBDZITQCWCBL-UHFFFAOYSA-N 4-chloro-n-[[4,4-difluoro-1-(4-propylsulfonylpiperazin-1-yl)cyclohexyl]methyl]-2-methylbenzamide Chemical compound C1CN(S(=O)(=O)CCC)CCN1C1(CNC(=O)C=2C(=CC(Cl)=CC=2)C)CCC(F)(F)CC1 FKLBDZITQCWCBL-UHFFFAOYSA-N 0.000 claims description 4
- COKPKOWZXUWPMW-UHFFFAOYSA-N 4-chloro-n-[[4,4-difluoro-1-[4-(1-methylimidazol-4-yl)sulfonylpiperazin-1-yl]cyclohexyl]methyl]-2-fluorobenzamide Chemical compound CN1C=NC(S(=O)(=O)N2CCN(CC2)C2(CNC(=O)C=3C(=CC(Cl)=CC=3)F)CCC(F)(F)CC2)=C1 COKPKOWZXUWPMW-UHFFFAOYSA-N 0.000 claims description 4
- UKHPDLGABCXRFF-UHFFFAOYSA-N 4-chloro-n-[[4,4-difluoro-1-[4-(1-methylimidazol-4-yl)sulfonylpiperazin-1-yl]cyclohexyl]methyl]-2-methylbenzamide Chemical compound CC1=CC(Cl)=CC=C1C(=O)NCC1(N2CCN(CC2)S(=O)(=O)C=2N=CN(C)C=2)CCC(F)(F)CC1 UKHPDLGABCXRFF-UHFFFAOYSA-N 0.000 claims description 4
- XDALBVGXFIUNBI-UHFFFAOYSA-N 4-chloro-n-[[4,4-difluoro-1-[4-(1-methyltriazol-4-yl)sulfonylpiperazin-1-yl]cyclohexyl]methyl]-2,5-difluorobenzamide Chemical compound N1=NN(C)C=C1S(=O)(=O)N1CCN(C2(CNC(=O)C=3C(=CC(Cl)=C(F)C=3)F)CCC(F)(F)CC2)CC1 XDALBVGXFIUNBI-UHFFFAOYSA-N 0.000 claims description 4
- DXUNCNNNBZUHMT-UHFFFAOYSA-N 4-chloro-n-[[4,4-difluoro-1-[4-(1-methyltriazol-4-yl)sulfonylpiperazin-1-yl]cyclohexyl]methyl]-2,6-difluorobenzamide Chemical compound N1=NN(C)C=C1S(=O)(=O)N1CCN(C2(CNC(=O)C=3C(=CC(Cl)=CC=3F)F)CCC(F)(F)CC2)CC1 DXUNCNNNBZUHMT-UHFFFAOYSA-N 0.000 claims description 4
- YVXNOVMSRCGLIH-UHFFFAOYSA-N C1CN(S(=O)(=O)CCC)CCN1C1(CNC(=O)C=2C(=CC(F)=C(F)C=2)Cl)CCC(F)(F)CC1 Chemical compound C1CN(S(=O)(=O)CCC)CCN1C1(CNC(=O)C=2C(=CC(F)=C(F)C=2)Cl)CCC(F)(F)CC1 YVXNOVMSRCGLIH-UHFFFAOYSA-N 0.000 claims description 4
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 4
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 4
- 125000001664 diethylamino group Chemical group [H]C([H])([H])C([H])([H])N(*)C([H])([H])C([H])([H])[H] 0.000 claims description 4
- 238000000034 method Methods 0.000 claims description 4
- TZWPZCDKEJCNJC-UHFFFAOYSA-N n-[1-[4,4-difluoro-1-[4-(1-methylimidazol-4-yl)sulfonylpiperazin-1-yl]cyclohexyl]ethyl]-2,6-difluorobenzamide Chemical compound C1CC(F)(F)CCC1(N1CCN(CC1)S(=O)(=O)C=1N=CN(C)C=1)C(C)NC(=O)C1=C(F)C=CC=C1F TZWPZCDKEJCNJC-UHFFFAOYSA-N 0.000 claims description 4
- VKYFTLGAORFNMG-UHFFFAOYSA-N n-[[1-[4-(cyclopropylmethylsulfonyl)piperazin-1-yl]cyclohexyl]methyl]-2-fluoro-6-methoxybenzamide Chemical compound COC1=CC=CC(F)=C1C(=O)NCC1(N2CCN(CC2)S(=O)(=O)CC2CC2)CCCCC1 VKYFTLGAORFNMG-UHFFFAOYSA-N 0.000 claims description 4
- GMSNDPCMIJNJLM-UHFFFAOYSA-N n-[[1-[4-(cyclopropylmethylsulfonyl)piperazin-1-yl]cyclohexyl]methyl]-2-fluoro-6-methylbenzamide Chemical compound CC1=CC=CC(F)=C1C(=O)NCC1(N2CCN(CC2)S(=O)(=O)CC2CC2)CCCCC1 GMSNDPCMIJNJLM-UHFFFAOYSA-N 0.000 claims description 4
- WNPIHHWODDWTLR-UHFFFAOYSA-N n-[[1-[4-(cyclopropylmethylsulfonyl)piperazin-1-yl]cyclohexyl]methyl]-4-fluoro-2-methoxy-6-methylbenzamide Chemical compound COC1=CC(F)=CC(C)=C1C(=O)NCC1(N2CCN(CC2)S(=O)(=O)CC2CC2)CCCCC1 WNPIHHWODDWTLR-UHFFFAOYSA-N 0.000 claims description 4
- NWMGHVKKINMYGI-UHFFFAOYSA-N n-[[4,4-difluoro-1-(4-propylsulfonylpiperazin-1-yl)cyclohexyl]methyl]-2,4,6-trifluorobenzamide Chemical compound C1CN(S(=O)(=O)CCC)CCN1C1(CNC(=O)C=2C(=CC(F)=CC=2F)F)CCC(F)(F)CC1 NWMGHVKKINMYGI-UHFFFAOYSA-N 0.000 claims description 4
- NDOFMSDUMFXXMI-UHFFFAOYSA-N n-[[4,4-difluoro-1-(4-propylsulfonylpiperazin-1-yl)cyclohexyl]methyl]-2,4-difluorobenzamide Chemical compound C1CN(S(=O)(=O)CCC)CCN1C1(CNC(=O)C=2C(=CC(F)=CC=2)F)CCC(F)(F)CC1 NDOFMSDUMFXXMI-UHFFFAOYSA-N 0.000 claims description 4
- QVWPBPKWGLPYEB-UHFFFAOYSA-N n-[[4,4-difluoro-1-(4-propylsulfonylpiperazin-1-yl)cyclohexyl]methyl]-2,6-dimethylbenzamide Chemical compound C1CN(S(=O)(=O)CCC)CCN1C1(CNC(=O)C=2C(=CC=CC=2C)C)CCC(F)(F)CC1 QVWPBPKWGLPYEB-UHFFFAOYSA-N 0.000 claims description 4
- RNSTUWINRMZUFI-UHFFFAOYSA-N n-[[4,4-difluoro-1-(4-propylsulfonylpiperazin-1-yl)cyclohexyl]methyl]-2-fluorobenzamide Chemical compound C1CN(S(=O)(=O)CCC)CCN1C1(CNC(=O)C=2C(=CC=CC=2)F)CCC(F)(F)CC1 RNSTUWINRMZUFI-UHFFFAOYSA-N 0.000 claims description 4
- AOYZCFQXYNJFCF-UHFFFAOYSA-N n-[[4,4-difluoro-1-(4-propylsulfonylpiperazin-1-yl)cyclohexyl]methyl]-2-methoxybenzamide Chemical compound C1CN(S(=O)(=O)CCC)CCN1C1(CNC(=O)C=2C(=CC=CC=2)OC)CCC(F)(F)CC1 AOYZCFQXYNJFCF-UHFFFAOYSA-N 0.000 claims description 4
- VAMGCMGZCLSJAC-UHFFFAOYSA-N n-[[4,4-difluoro-1-(4-propylsulfonylpiperazin-1-yl)cyclohexyl]methyl]-2-methylbenzamide Chemical compound C1CN(S(=O)(=O)CCC)CCN1C1(CNC(=O)C=2C(=CC=CC=2)C)CCC(F)(F)CC1 VAMGCMGZCLSJAC-UHFFFAOYSA-N 0.000 claims description 4
- OTOCKFNXNPZZMQ-UHFFFAOYSA-N n-[[4,4-difluoro-1-(4-propylsulfonylpiperazin-1-yl)cyclohexyl]methyl]-4-fluoro-2-methoxy-6-methylbenzamide Chemical compound C1CN(S(=O)(=O)CCC)CCN1C1(CNC(=O)C=2C(=CC(F)=CC=2C)OC)CCC(F)(F)CC1 OTOCKFNXNPZZMQ-UHFFFAOYSA-N 0.000 claims description 4
- AMGDFUGZEFTRAI-UHFFFAOYSA-N n-[[4,4-difluoro-1-(4-propylsulfonylpiperazin-1-yl)cyclohexyl]methyl]-4-fluoro-2-methylbenzamide Chemical compound C1CN(S(=O)(=O)CCC)CCN1C1(CNC(=O)C=2C(=CC(F)=CC=2)C)CCC(F)(F)CC1 AMGDFUGZEFTRAI-UHFFFAOYSA-N 0.000 claims description 4
- HVOMUXKZVGTQLD-UHFFFAOYSA-N n-[[4,4-difluoro-1-[4-(1-methylimidazol-4-yl)sulfonylpiperazin-1-yl]cyclohexyl]methyl]-2,4,6-trifluorobenzamide Chemical compound CN1C=NC(S(=O)(=O)N2CCN(CC2)C2(CNC(=O)C=3C(=CC(F)=CC=3F)F)CCC(F)(F)CC2)=C1 HVOMUXKZVGTQLD-UHFFFAOYSA-N 0.000 claims description 4
- QSGFPXUMGFCOFY-UHFFFAOYSA-N n-[[4,4-difluoro-1-[4-(1-methylimidazol-4-yl)sulfonylpiperazin-1-yl]cyclohexyl]methyl]-2,6-dimethylbenzamide Chemical compound CC1=CC=CC(C)=C1C(=O)NCC1(N2CCN(CC2)S(=O)(=O)C=2N=CN(C)C=2)CCC(F)(F)CC1 QSGFPXUMGFCOFY-UHFFFAOYSA-N 0.000 claims description 4
- WQQHAJUQEIVQBL-UHFFFAOYSA-N n-[[4,4-difluoro-1-[4-(1-methylimidazol-4-yl)sulfonylpiperazin-1-yl]cyclohexyl]methyl]-2-fluoro-6-methylbenzamide Chemical compound CC1=CC=CC(F)=C1C(=O)NCC1(N2CCN(CC2)S(=O)(=O)C=2N=CN(C)C=2)CCC(F)(F)CC1 WQQHAJUQEIVQBL-UHFFFAOYSA-N 0.000 claims description 4
- ZNWCVLQSKAXUSJ-UHFFFAOYSA-N n-[[4,4-difluoro-1-[4-(1-methylimidazol-4-yl)sulfonylpiperazin-1-yl]cyclohexyl]methyl]-2-fluorobenzamide Chemical compound CN1C=NC(S(=O)(=O)N2CCN(CC2)C2(CNC(=O)C=3C(=CC=CC=3)F)CCC(F)(F)CC2)=C1 ZNWCVLQSKAXUSJ-UHFFFAOYSA-N 0.000 claims description 4
- DETQBEXCWDNDRW-UHFFFAOYSA-N n-[[4,4-difluoro-1-[4-(1-methylimidazol-4-yl)sulfonylpiperazin-1-yl]cyclohexyl]methyl]-2-methoxybenzamide Chemical compound COC1=CC=CC=C1C(=O)NCC1(N2CCN(CC2)S(=O)(=O)C=2N=CN(C)C=2)CCC(F)(F)CC1 DETQBEXCWDNDRW-UHFFFAOYSA-N 0.000 claims description 4
- IMIBJNYSGZKCNA-UHFFFAOYSA-N n-[[4,4-difluoro-1-[4-(1-methylimidazol-4-yl)sulfonylpiperazin-1-yl]cyclohexyl]methyl]-2-methylbenzamide Chemical compound CC1=CC=CC=C1C(=O)NCC1(N2CCN(CC2)S(=O)(=O)C=2N=CN(C)C=2)CCC(F)(F)CC1 IMIBJNYSGZKCNA-UHFFFAOYSA-N 0.000 claims description 4
- DZJAQFYLBKJLSC-UHFFFAOYSA-N n-[[4,4-difluoro-1-[4-(1-methyltriazol-4-yl)sulfonylpiperazin-1-yl]cyclohexyl]methyl]-2,4-difluorobenzamide Chemical compound N1=NN(C)C=C1S(=O)(=O)N1CCN(C2(CNC(=O)C=3C(=CC(F)=CC=3)F)CCC(F)(F)CC2)CC1 DZJAQFYLBKJLSC-UHFFFAOYSA-N 0.000 claims description 4
- AAJKPXOKLARRLN-UHFFFAOYSA-N n-[[4,4-difluoro-1-[4-(1-methyltriazol-4-yl)sulfonylpiperazin-1-yl]cyclohexyl]methyl]-2,5-difluoro-4-methylbenzamide Chemical compound C1=C(F)C(C)=CC(F)=C1C(=O)NCC1(N2CCN(CC2)S(=O)(=O)C=2N=NN(C)C=2)CCC(F)(F)CC1 AAJKPXOKLARRLN-UHFFFAOYSA-N 0.000 claims description 4
- 125000004482 piperidin-4-yl group Chemical group N1CCC(CC1)* 0.000 claims description 4
- 125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 claims description 3
- 230000002401 inhibitory effect Effects 0.000 claims description 3
- MCZHJXJZKUUYPH-UHFFFAOYSA-N n-[[4,4-difluoro-1-(4-propylsulfonylpiperazin-1-yl)cyclohexyl]methyl]-2-fluoro-6-methylbenzamide Chemical compound C1CN(S(=O)(=O)CCC)CCN1C1(CNC(=O)C=2C(=CC=CC=2C)F)CCC(F)(F)CC1 MCZHJXJZKUUYPH-UHFFFAOYSA-N 0.000 claims description 3
- PULRKCRDZUKOKS-UHFFFAOYSA-N n-[[4,4-difluoro-1-[4-(1-methylimidazol-4-yl)sulfonylpiperazin-1-yl]cyclohexyl]methyl]-4-fluoro-2-methylbenzamide Chemical compound CC1=CC(F)=CC=C1C(=O)NCC1(N2CCN(CC2)S(=O)(=O)C=2N=CN(C)C=2)CCC(F)(F)CC1 PULRKCRDZUKOKS-UHFFFAOYSA-N 0.000 claims description 3
- 125000006002 1,1-difluoroethyl group Chemical group 0.000 claims description 2
- YSBFNDZSWOOXIK-UHFFFAOYSA-N 2,4-dichloro-n-[[1-(4-ethylsulfonylpiperazin-1-yl)-4,4-difluorocyclohexyl]methyl]-5-fluorobenzamide Chemical compound C1CN(S(=O)(=O)CC)CCN1C1(CNC(=O)C=2C(=CC(Cl)=C(F)C=2)Cl)CCC(F)(F)CC1 YSBFNDZSWOOXIK-UHFFFAOYSA-N 0.000 claims description 2
- BKGLNMKBEQVUAV-UHFFFAOYSA-N 2,4-dichloro-n-[[1-(4-ethylsulfonylpiperazin-1-yl)-4,4-difluorocyclohexyl]methyl]-6-fluorobenzamide Chemical compound C1CN(S(=O)(=O)CC)CCN1C1(CNC(=O)C=2C(=CC(Cl)=CC=2F)Cl)CCC(F)(F)CC1 BKGLNMKBEQVUAV-UHFFFAOYSA-N 0.000 claims description 2
- WEGDNAKNVHYJFL-UHFFFAOYSA-N 2,4-dichloro-n-[[4,4-difluoro-1-(4-propylsulfonylpiperazin-1-yl)cyclohexyl]methyl]-5-fluorobenzamide Chemical compound C1CN(S(=O)(=O)CCC)CCN1C1(CNC(=O)C=2C(=CC(Cl)=C(F)C=2)Cl)CCC(F)(F)CC1 WEGDNAKNVHYJFL-UHFFFAOYSA-N 0.000 claims description 2
- PTHHLXFTNODSHI-UHFFFAOYSA-N 2-chloro-n-[[1-(4-ethylsulfonylpiperazin-1-yl)-4,4-difluorocyclohexyl]methyl]-4,5-difluorobenzamide Chemical compound C1CN(S(=O)(=O)CC)CCN1C1(CNC(=O)C=2C(=CC(F)=C(F)C=2)Cl)CCC(F)(F)CC1 PTHHLXFTNODSHI-UHFFFAOYSA-N 0.000 claims description 2
- ZKWVLUXSYUKFAV-UHFFFAOYSA-N 2-chloro-n-[[4,4-difluoro-1-(4-propylsulfonylpiperazin-1-yl)cyclohexyl]methyl]-6-methoxybenzamide Chemical compound C1CN(S(=O)(=O)CCC)CCN1C1(CNC(=O)C=2C(=CC=CC=2Cl)OC)CCC(F)(F)CC1 ZKWVLUXSYUKFAV-UHFFFAOYSA-N 0.000 claims description 2
- KVDLAMSUAUKUKO-UHFFFAOYSA-N 2-chloro-n-[[4,4-difluoro-1-[4-(2-oxopropylsulfonyl)piperazin-1-yl]cyclohexyl]methyl]-4-(trifluoromethyl)benzamide Chemical compound C1CN(S(=O)(=O)CC(=O)C)CCN1C1(CNC(=O)C=2C(=CC(=CC=2)C(F)(F)F)Cl)CCC(F)(F)CC1 KVDLAMSUAUKUKO-UHFFFAOYSA-N 0.000 claims description 2
- HKKUPICUGZURGJ-UHFFFAOYSA-N 4-chloro-n-[[1-(4-ethylsulfonylpiperazin-1-yl)-4,4-difluorocyclohexyl]methyl]-2,6-difluorobenzamide Chemical compound C1CN(S(=O)(=O)CC)CCN1C1(CNC(=O)C=2C(=CC(Cl)=CC=2F)F)CCC(F)(F)CC1 HKKUPICUGZURGJ-UHFFFAOYSA-N 0.000 claims description 2
- QUDSWCZDNSOGSV-UHFFFAOYSA-N 4-phenyl-n-[[1-(4-propylsulfonylpiperazin-1-yl)cyclohexyl]methyl]benzamide Chemical compound C1CN(S(=O)(=O)CCC)CCN1C1(CNC(=O)C=2C=CC(=CC=2)C=2C=CC=CC=2)CCCCC1 QUDSWCZDNSOGSV-UHFFFAOYSA-N 0.000 claims description 2
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims description 2
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical group C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 claims description 2
- HONIICLYMWZJFZ-UHFFFAOYSA-N azetidine Chemical compound C1CNC1 HONIICLYMWZJFZ-UHFFFAOYSA-N 0.000 claims description 2
- 150000001975 deuterium Chemical group 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims description 2
- RBTVQIGCZOVNTC-UHFFFAOYSA-N n-[1-[4,4-difluoro-1-(4-propylsulfonylpiperazin-1-yl)cyclohexyl]ethyl]-2,6-difluorobenzamide Chemical compound C1CN(S(=O)(=O)CCC)CCN1C1(C(C)NC(=O)C=2C(=CC=CC=2F)F)CCC(F)(F)CC1 RBTVQIGCZOVNTC-UHFFFAOYSA-N 0.000 claims description 2
- XHSQIVZZASGJNU-UHFFFAOYSA-N n-[[1-(4-ethylsulfonylpiperazin-1-yl)-4,4-difluorocyclohexyl]methyl]-2,4,6-trimethylbenzamide Chemical compound C1CN(S(=O)(=O)CC)CCN1C1(CNC(=O)C=2C(=CC(C)=CC=2C)C)CCC(F)(F)CC1 XHSQIVZZASGJNU-UHFFFAOYSA-N 0.000 claims description 2
- RWEUEXUKXFRXHU-UHFFFAOYSA-N n-[[1-(4-ethylsulfonylpiperazin-1-yl)cycloheptyl]methyl]-4-fluoro-2-methoxy-6-methylbenzamide Chemical compound C1CN(S(=O)(=O)CC)CCN1C1(CNC(=O)C=2C(=CC(F)=CC=2C)OC)CCCCCC1 RWEUEXUKXFRXHU-UHFFFAOYSA-N 0.000 claims description 2
- ATUATULGTKTCRC-UHFFFAOYSA-N n-[[1-[4-(azetidin-1-ylsulfonyl)piperazin-1-yl]-4,4-difluorocyclohexyl]methyl]-2-chloro-4-(trifluoromethyl)benzamide Chemical compound ClC1=CC(C(F)(F)F)=CC=C1C(=O)NCC1(N2CCN(CC2)S(=O)(=O)N2CCC2)CCC(F)(F)CC1 ATUATULGTKTCRC-UHFFFAOYSA-N 0.000 claims description 2
- WKKQODFDAALQAP-UHFFFAOYSA-N n-[[1-[4-(cyclopropylmethylsulfonyl)piperazin-1-yl]cycloheptyl]methyl]-4-fluoro-2-methoxy-6-methylbenzamide Chemical compound COC1=CC(F)=CC(C)=C1C(=O)NCC1(N2CCN(CC2)S(=O)(=O)CC2CC2)CCCCCC1 WKKQODFDAALQAP-UHFFFAOYSA-N 0.000 claims description 2
- OETWRGXSSHUXGO-UHFFFAOYSA-N n-[[1-[4-(cyclopropylmethylsulfonyl)piperazin-1-yl]cycloheptyl]methyl]-4-fluoro-2-methylbenzamide Chemical compound CC1=CC(F)=CC=C1C(=O)NCC1(N2CCN(CC2)S(=O)(=O)CC2CC2)CCCCCC1 OETWRGXSSHUXGO-UHFFFAOYSA-N 0.000 claims description 2
- AHFGYPSLUCEMSR-UHFFFAOYSA-N n-[[1-[4-(cyclopropylmethylsulfonyl)piperazin-1-yl]cyclohexyl]methyl]-2,6-difluorobenzamide Chemical compound FC1=CC=CC(F)=C1C(=O)NCC1(N2CCN(CC2)S(=O)(=O)CC2CC2)CCCCC1 AHFGYPSLUCEMSR-UHFFFAOYSA-N 0.000 claims description 2
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 8
- SNOOUWRIMMFWNE-UHFFFAOYSA-M sodium;6-[(3,4,5-trimethoxybenzoyl)amino]hexanoate Chemical compound [Na+].COC1=CC(C(=O)NCCCCCC([O-])=O)=CC(OC)=C1OC SNOOUWRIMMFWNE-UHFFFAOYSA-M 0.000 claims 8
- XTFIVUDBNACUBN-UHFFFAOYSA-N 1,3,5-trinitro-1,3,5-triazinane Chemical compound [O-][N+](=O)N1CN([N+]([O-])=O)CN([N+]([O-])=O)C1 XTFIVUDBNACUBN-UHFFFAOYSA-N 0.000 claims 2
- HSOQDPYTTOKEHI-UHFFFAOYSA-N 2-methylsulfanylbenzamide Chemical compound CSC1=CC=CC=C1C(N)=O HSOQDPYTTOKEHI-UHFFFAOYSA-N 0.000 claims 2
- 238000006243 chemical reaction Methods 0.000 claims 2
- 125000000725 trifluoropropyl group Chemical group [H]C([H])(*)C([H])([H])C(F)(F)F 0.000 claims 2
- 125000004070 6 membered heterocyclic group Chemical group 0.000 claims 1
- 125000003341 7 membered heterocyclic group Chemical group 0.000 claims 1
- 102100023145 Sodium- and chloride-dependent glycine transporter 1 Human genes 0.000 claims 1
- 101710083171 Sodium- and chloride-dependent glycine transporter 1 Proteins 0.000 claims 1
- 239000000126 substance Substances 0.000 description 29
- 102000010726 Glycine Plasma Membrane Transport Proteins Human genes 0.000 description 5
- 108010063380 Glycine Plasma Membrane Transport Proteins Proteins 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- WNCQMSAPMWRZNY-UHFFFAOYSA-N n-[[4,4-difluoro-1-[4-(1-methyltriazol-4-yl)sulfonylpiperazin-1-yl]cyclohexyl]methyl]-2,4,6-trifluorobenzamide Chemical compound N1=NN(C)C=C1S(=O)(=O)N1CCN(C2(CNC(=O)C=3C(=CC(F)=CC=3F)F)CCC(F)(F)CC2)CC1 WNCQMSAPMWRZNY-UHFFFAOYSA-N 0.000 description 2
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- NRFLBUBZPQPDCV-UHFFFAOYSA-N n-(difluoromethoxy)benzamide Chemical compound FC(F)ONC(=O)C1=CC=CC=C1 NRFLBUBZPQPDCV-UHFFFAOYSA-N 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 230000024587 synaptic transmission, glutamatergic Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US35166210P | 2010-06-04 | 2010-06-04 | |
| US61/351,662 | 2010-06-04 | ||
| PCT/US2011/038939 WO2011153359A1 (en) | 2010-06-04 | 2011-06-02 | Glycine transporter-1 inhibitors, methods of making them, and uses thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013530957A JP2013530957A (ja) | 2013-08-01 |
| JP2013530957A5 true JP2013530957A5 (cg-RX-API-DMAC7.html) | 2014-07-10 |
| JP5813101B2 JP5813101B2 (ja) | 2015-11-17 |
Family
ID=45067074
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013513348A Expired - Fee Related JP5813101B2 (ja) | 2010-06-04 | 2011-06-02 | グリシントランスポーター−１阻害剤、その作製方法および使用方法 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US9045445B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP2575815A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP5813101B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR20130087002A (cg-RX-API-DMAC7.html) |
| CN (1) | CN103096893B (cg-RX-API-DMAC7.html) |
| AU (1) | AU2011261375B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2801074A1 (cg-RX-API-DMAC7.html) |
| NZ (1) | NZ604035A (cg-RX-API-DMAC7.html) |
| SG (1) | SG186885A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2011153359A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2344453B1 (en) * | 2008-10-09 | 2016-12-28 | The U.S.A. As Represented By The Secretary, Department Of Health And Human Services | Activators of human pyruvate kinase |
| JP5756457B2 (ja) | 2009-04-06 | 2015-07-29 | アジオス ファーマシューティカルズ， インコーポレイテッド | ピルビン酸キナーゼｍ２調節剤、治療組成物および関連する使用方法 |
| CA2760929C (en) | 2009-05-04 | 2018-01-02 | Agios Pharmaceuticals, Inc. | Pkm2 activators for use in the treatment of cancer |
| US8785450B2 (en) | 2009-06-29 | 2014-07-22 | Agios Pharmaceuticals, Inc. | Therapeutic compounds and compositions |
| EP2448581B1 (en) | 2009-06-29 | 2016-12-07 | Agios Pharmaceuticals, Inc. | Therapeutic compositions and related methods of use |
| EP2563761A1 (en) | 2010-04-29 | 2013-03-06 | The U.S.A. As Represented By The Secretary, Department Of Health And Human Services | Activators of human pyruvate kinase |
| JP5813101B2 (ja) | 2010-06-04 | 2015-11-17 | アルバニー モレキュラー リサーチ， インコーポレイテッド | グリシントランスポーター−１阻害剤、その作製方法および使用方法 |
| US9221792B2 (en) | 2010-12-17 | 2015-12-29 | Agios Pharmaceuticals, Inc | N-(4-(azetidine-1-carbonyl) phenyl)-(hetero-) arylsulfonamide derivatives as pyruvate kinase M2 (PMK2) modulators |
| EP2655350B1 (en) | 2010-12-21 | 2016-03-09 | Agios Pharmaceuticals, Inc. | Bicyclic pkm2 activators |
| TWI549947B (zh) | 2010-12-29 | 2016-09-21 | 阿吉歐斯製藥公司 | 治療化合物及組成物 |
| WO2012151451A1 (en) | 2011-05-03 | 2012-11-08 | Agios Pharmaceuticals, Inc. | Pyruvate kinase activators for use in therapy |
| CN103254127B (zh) * | 2013-05-28 | 2015-08-19 | 北京哈三联科技有限责任公司 | 甘氨酸重摄取抑制剂及其应用 |
| MA44392B1 (fr) | 2015-06-11 | 2023-10-31 | Agios Pharmaceuticals Inc | Procédés d'utilisation d'activateurs de la pyruvate kinase |
| WO2016202161A1 (zh) | 2015-06-16 | 2016-12-22 | 江苏恒瑞医药股份有限公司 | 哌啶类衍生物、其制备方法及其在医药上的应用 |
Family Cites Families (186)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3145209A (en) | 1961-07-31 | 1964-08-18 | Olin Mathieson | Substituted aminophenyl-ethylamine derivatives |
| US3975443A (en) | 1972-06-06 | 1976-08-17 | Allen & Hanburys Limited | 1-(3,4-dichlorobenzamidomethyl)-cyclohexyldimethylamine |
| DE3718317A1 (de) | 1986-12-10 | 1988-06-16 | Bayer Ag | Substituierte basische 2-aminotetraline |
| US5032604A (en) | 1989-12-08 | 1991-07-16 | Merck & Co., Inc. | Class III antiarrhythmic agents |
| DE4302051A1 (de) | 1993-01-26 | 1994-07-28 | Thomae Gmbh Dr K | 5-gliedrige Heterocyclen, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel |
| DK0687268T3 (da) | 1993-03-04 | 1998-10-12 | Pfizer | Spiroazacykliske derivater som substans P-antagonister |
| DE69430483D1 (de) | 1993-07-16 | 2002-05-29 | Merck & Co Inc | Benzoxazinon- und Benzopyrimidinon- piperidinyl-Verbindungen als tokolytische Oxytocin-Rezeptor-Antagonisten |
| US5464788A (en) | 1994-03-24 | 1995-11-07 | Merck & Co., Inc. | Tocolytic oxytocin receptor antagonists |
| PL318298A1 (en) | 1994-07-20 | 1997-06-09 | Byk Gulden Lomberg Chem Fab | Thiopyridil compounds for fighting against heliobacter |
| FR2731222A1 (fr) | 1995-03-02 | 1996-09-06 | Pf Medicament | Nouveaux derives de piperazine aminoindoles cycliques, leur procede de preparation et leur utilisation a titre de medicaments |
| US5856326A (en) | 1995-03-29 | 1999-01-05 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
| US5939418A (en) | 1995-12-21 | 1999-08-17 | The Dupont Merck Pharmaceutical Company | Isoxazoline, isothiazoline and pyrazoline factor Xa inhibitors |
| DE19548624A1 (de) | 1995-12-23 | 1997-06-26 | Boehringer Mannheim Gmbh | Neue Barbitursäure-Derivate, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel |
| US6333322B1 (en) | 1996-03-13 | 2001-12-25 | Eisai Co., Ltd. | Nitrogen-containing tricyclic compounds and drugs containing the same |
| US5919785A (en) | 1996-04-03 | 1999-07-06 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
| US5885995A (en) | 1996-04-03 | 1999-03-23 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
| AU707347B2 (en) | 1996-04-03 | 1999-07-08 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
| US5859012A (en) | 1996-04-03 | 1999-01-12 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
| CA2249559A1 (en) | 1996-04-03 | 1997-10-09 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
| DE19700431A1 (de) | 1997-01-10 | 1998-07-16 | Basf Ag | Reaktivfarbstoffe mit einem Disulfonylanker |
| US6060038A (en) | 1997-05-15 | 2000-05-09 | Merck & Co., Inc. | Radiolabeled farnesyl-protein transferase inhibitors |
| WO1999040075A1 (en) | 1998-02-05 | 1999-08-12 | Takeda Chemical Industries, Ltd. | Sulfonamide derivatives, process for producing the same and utilization thereof |
| GB9806287D0 (en) | 1998-03-24 | 1998-05-20 | Synphar Lab Inc | Monobactam enzyme inhibitors |
| TWI220143B (en) | 1998-05-13 | 2004-08-11 | Solvay Pharm Gmbh | Method for stereochemically controlled production of isomerically pure highly substituted azacyclic compounds and novel cyclic compounds, and intermediate products |
| US6380193B1 (en) | 1998-05-15 | 2002-04-30 | Guilford Pharmaceuticals Inc. | Fused tricyclic compounds, methods and compositions for inhibiting PARP activity |
| EP1077946A1 (en) | 1998-05-15 | 2001-02-28 | Guilford Pharmaceuticals Inc. | Fused tricyclic compounds which inhibit parp activity |
| US6509338B1 (en) | 1998-06-22 | 2003-01-21 | Bristol-Myers Squibb Company | Pyrazolo[1,5-A]triazine corticotropin releasing factor antagonists |
| US6632836B1 (en) | 1998-10-30 | 2003-10-14 | Merck & Co., Inc. | Carbocyclic potassium channel inhibitors |
| AU3215500A (en) | 1999-01-25 | 2000-08-07 | Smithkline Beecham Corporation | Compounds and methods |
| CA2362495A1 (en) | 1999-03-03 | 2000-09-08 | Theresa M. Williams | Inhibitors of prenyl-protein transferases |
| EP1165013A4 (en) | 1999-03-03 | 2002-08-07 | Merck & Co Inc | INHIBITORS OF PHENYL PROTEIN TRANSFERASE |
| US6358956B1 (en) | 1999-03-03 | 2002-03-19 | Merck & Co., Inc. | Inhibitors of prenyl-protein transferase |
| JP2003524618A (ja) | 1999-03-03 | 2003-08-19 | メルク エンド カムパニー インコーポレーテッド | プレニル蛋白トランスフェラーゼ阻害剤 |
| CA2362494A1 (en) | 1999-03-03 | 2000-09-08 | Merck & Co., Inc. | Inhibitors of prenyl-protein transferase |
| DE19911509A1 (de) | 1999-03-15 | 2000-09-21 | Boehringer Ingelheim Pharma | Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung |
| DE19911510A1 (de) | 1999-03-15 | 2000-09-21 | Boehringer Ingelheim Pharma | Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung |
| AU5464200A (en) | 1999-06-09 | 2000-12-28 | Merck & Co., Inc. | Biaryl inhibitors of prenyl-protein transferase |
| AU5567000A (en) | 1999-06-24 | 2001-01-09 | Toray Industries, Inc. | Alpha1b-adrenergic receptor antagonists |
| AU6936500A (en) | 1999-08-24 | 2001-03-19 | Regents Of The University Of California, The | Non-quinoline inhibitors of malaria parasites |
| DE19944066A1 (de) | 1999-09-14 | 2001-03-15 | Byk Gulden Lomberg Chem Fab | Inhibitoren der Tryptase |
| WO2001022963A1 (en) | 1999-09-27 | 2001-04-05 | Merck & Co., Inc. | Method of preventing osteoporosis |
| CN1374961A (zh) | 1999-09-28 | 2002-10-16 | 巴斯福股份公司 | 氮杂䓬吲哚衍生物,它们的制备和应用 |
| US20020010184A1 (en) | 2000-02-18 | 2002-01-24 | Dinsmore Christopher J. | Inhibitors of prenyl-protein transferase |
| US20020052380A1 (en) | 2000-02-18 | 2002-05-02 | Dinsmore Christopher J. | Inhibitors of prenyl-protein transferase |
| US20040110764A1 (en) | 2000-04-10 | 2004-06-10 | Stump Craig A. | Inhibitors of prenyl-protein transferase |
| GB0012214D0 (en) | 2000-05-19 | 2000-07-12 | Merck Sharp & Dohme | Therapeutic agents |
| AU2002211280A1 (en) | 2000-09-29 | 2002-04-08 | Cor Therapeutics, Inc. | Piperazin-2-one amides as inhibitors of factor Xa |
| US20020124273A1 (en) | 2000-10-17 | 2002-09-05 | Jean-Marc Roch | Protein-protein interactions in neurodegenerative diseases |
| US20040180925A1 (en) | 2000-12-27 | 2004-09-16 | Kenji Matsuno | Dipeptidylpeptidase-IV inhibitor |
| SE0100902D0 (sv) | 2001-03-15 | 2001-03-15 | Astrazeneca Ab | Compounds |
| US20030158209A1 (en) | 2001-10-09 | 2003-08-21 | Neurocrine Biosciences Inc. | Ligands of melanocortin receptors and compositions and methods related thereto |
| US7294624B2 (en) | 2001-12-20 | 2007-11-13 | Bristol Myers Squibb Company | Barbituric acid derivatives as inhibitors of TNF-α converting enzyme (TACE) and/or matrix metalloproteinases |
| US6936620B2 (en) | 2001-12-20 | 2005-08-30 | Bristol Myers Squibb Company | Barbituric acid derivatives as inhibitors of TNF-α converting enzyme (TACE) and/or matrix metalloproteinases |
| EP1469851B1 (en) | 2002-01-23 | 2006-10-11 | Eli Lilly And Company | Melanocortin receptor agonists |
| MXPA04009490A (es) | 2002-04-03 | 2005-06-08 | Topo Target Uk Ltd | Compuesto de acido carbamico que comprenden un enlace de piperazina como inhibidores de histona desacetilasa. |
| ATE529112T1 (de) | 2002-04-18 | 2011-11-15 | Schering Corp | 1-(4-piperidinyl)benzimidazolone als histamin h3 antagonisten |
| US7105505B2 (en) | 2002-04-18 | 2006-09-12 | Schering Corporation | Benzimidazole derivatives useful as histamine H3 antagonists |
| MXPA04010555A (es) | 2002-04-25 | 2005-02-17 | Pharmacia Corp | Acidos piperidinil- y piperazinil-sulfonilmetil hidroxamicos y su uso como inhibidores de proteasa. |
| US20050209278A1 (en) | 2002-04-25 | 2005-09-22 | Mcdonald Joseph J | Piperidinyl- and piperazinyl-sulfonylmethyl hydroxamic acids and their use as protease inhibitors |
| DE60309598T2 (de) | 2002-06-24 | 2007-09-13 | Schering Corp. | Als histamin-h3-antagonisten geeignete indolderivate |
| US6906096B2 (en) | 2002-06-28 | 2005-06-14 | Irm Llc | 4,7-Disubstituted indoles and methods of making |
| AU2003259131A1 (en) | 2002-07-09 | 2004-01-23 | Bristol-Myers Squibb Company | Substituted heterocyclic derivatives useful as antidiabetic and antiobesity agents and method |
| WO2004010942A2 (en) | 2002-07-31 | 2004-02-05 | Smithkline Beecham Corporation | Substituted heterocyclic compounds as modulators of the ccr5 receptor |
| AU2003299124A1 (en) | 2002-09-20 | 2004-04-23 | Laboratoires Serono Sa | Piperazine derivatives and methods of use |
| AU2003275632A1 (en) | 2002-10-25 | 2004-05-13 | Mitsubishi Pharma Corporation | N-oxide compounds |
| US7452911B2 (en) | 2002-10-31 | 2008-11-18 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Alkyne compounds with MCH antagonistic activity and medicaments comprising these compounds |
| WO2004081643A1 (en) | 2002-12-20 | 2004-09-23 | Kaiser Aerospace & Electronics Corp. | Lenslet array with polarization conversion |
| US6861422B2 (en) | 2003-02-26 | 2005-03-01 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Dihydropteridinones, processes for preparing them and their use as pharmaceutical compositions |
| US20050043533A1 (en) | 2003-03-25 | 2005-02-24 | Babiak Kevin A. | Process for making alpha-substituted hydroxamic acids |
| WO2004099179A1 (en) | 2003-05-07 | 2004-11-18 | Actelion Pharmaceuticals Ltd | Piperazine-alkyl-ureido derivatives |
| DE602004022819D1 (de) | 2003-06-06 | 2009-10-08 | Vertex Pharma | Von atp-bindende kassette transportern |
| US7705052B2 (en) * | 2003-09-12 | 2010-04-27 | Merck Serono Sa | Sulfonamide derivatives for the treatment of diabetes |
| US20050124625A1 (en) | 2003-10-21 | 2005-06-09 | Salvati Mark E. | Piperazine derivatives and their use as modulators of nuclear hormone receptor function |
| US20050192286A1 (en) | 2003-10-22 | 2005-09-01 | Neurocrine Biosciences, Inc. | Ligands of melanocortin receptors and compositions and methods related thereto |
| GB0325956D0 (en) | 2003-11-06 | 2003-12-10 | Addex Pharmaceuticals Sa | Novel compounds |
| GB0328900D0 (en) | 2003-12-12 | 2004-01-14 | Glaxo Group Ltd | Novel compounds |
| EP1695961A4 (en) | 2003-12-17 | 2007-10-24 | Takeda Pharmaceutical | UREA DERIVATIVE, METHOD FOR THE PRODUCTION AND THEIR USE |
| JP2007515490A (ja) | 2003-12-22 | 2007-06-14 | アムジェン インコーポレーティッド | アリールスルホンアミド化合物およびそれに関連する使用法 |
| JP2005232306A (ja) | 2004-02-19 | 2005-09-02 | Fuji Photo Film Co Ltd | 光重合性組成物及びそれを用いた記録材料 |
| TW200538433A (en) | 2004-02-24 | 2005-12-01 | Irm Llc | Immunosuppressant compounds and compositiions |
| US20080004263A1 (en) | 2004-03-04 | 2008-01-03 | Santora Vincent J | Ligands of Follicle Stimulating Hormone Receptor and Methods of Use Thereof |
| US20050197336A1 (en) | 2004-03-08 | 2005-09-08 | Miikana Therapeutics Corporation | Inhibitors of histone deacetylase |
| EP1744751A4 (en) | 2004-03-18 | 2010-03-10 | Brigham & Womens Hospital | METHOD FOR THE TREATMENT OF SYNUCLEINOPATHIES |
| SE0400850D0 (sv) | 2004-03-30 | 2004-03-31 | Astrazeneca Ab | Novel Compounds |
| US7345043B2 (en) | 2004-04-01 | 2008-03-18 | Miikana Therapeutics | Inhibitors of histone deacetylase |
| GB0408777D0 (en) * | 2004-04-20 | 2004-05-26 | Glaxo Group Ltd | Compounds |
| US20050250789A1 (en) | 2004-04-20 | 2005-11-10 | Burns David M | Hydroxamic acid derivatives as metalloprotease inhibitors |
| US7880001B2 (en) | 2004-04-29 | 2011-02-01 | Abbott Laboratories | Inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme |
| BRPI0510664B8 (pt) | 2004-05-07 | 2021-05-25 | Warner Lambert Co | derivados de fenol e tiofenol 3 ou 4-monosubstituído, composição farmacêutica, combinação e uso dos compostos para tratamento de doenças relacionadas ao h3, incluindo transtornos do sistema nervoso central e transtornos inflamatórios |
| WO2005115374A1 (en) | 2004-05-29 | 2005-12-08 | 7Tm Pharma A/S | Crth2 receptor ligands for therapeutic use |
| MXPA06013675A (es) | 2004-06-08 | 2007-02-13 | Pfizer Prod Inc | Antagonistas de nk1. |
| US20060241118A1 (en) | 2004-06-18 | 2006-10-26 | Celltech R&D Limited | Hydroxamate sulfonamides as cd23 shedding inhibitors |
| US7553838B2 (en) | 2004-07-01 | 2009-06-30 | Merck & Co. Inc. | Mitotic kinesin inhibitors |
| WO2006008644A1 (en) | 2004-07-13 | 2006-01-26 | Pfizer Products Inc. | Antidiabetic compounds |
| US7226931B2 (en) | 2004-07-22 | 2007-06-05 | Cumbre Pharmaceuticals Inc. | (R/S) rifamycin derivatives, their preparations and pharmaceutical compositions |
| SE0401971D0 (sv) | 2004-08-02 | 2004-08-02 | Astrazeneca Ab | Piperidne derivatives |
| US20060074088A1 (en) | 2004-08-14 | 2006-04-06 | Boehringer Ingelheim International Gmbh | Dihydropteridinones for the treatment of cancer diseases |
| US20060058311A1 (en) | 2004-08-14 | 2006-03-16 | Boehringer Ingelheim International Gmbh | Combinations for the treatment of diseases involving cell proliferation |
| PE20060653A1 (es) | 2004-08-31 | 2006-09-27 | Glaxo Group Ltd | Derivados triciclicos condensados como moduladores del receptor 5-ht1 |
| EP1804792A1 (en) | 2004-09-20 | 2007-07-11 | Xenon Pharmaceuticals Inc. | Bicyclic heterocyclic derivatives and their use as inhibitors of stearoyl-coa-desaturase (scd) |
| AR051026A1 (es) | 2004-09-20 | 2006-12-13 | Xenon Pharmaceuticals Inc | Derivados heterociclicos y su uso como inhibidores de la estearoil-coa desaturasa |
| BRPI0515505A (pt) | 2004-09-20 | 2008-07-29 | Xenon Pharmaceuticals Inc | derivados heterocìclicos e sua utilização como inibidores da estearoil-coa desaturase |
| US8778874B2 (en) | 2004-11-29 | 2014-07-15 | National University Corporation Nagoya University | Glycopeptide antibiotic monomer derivatives |
| AU2005313581B2 (en) * | 2004-12-09 | 2011-06-09 | F. Hoffmann-La Roche Ag | Phenyl-piperazin methanone derivatives |
| GB0428233D0 (en) | 2004-12-23 | 2005-01-26 | Glaxo Group Ltd | Compounds |
| PE20061330A1 (es) | 2004-12-23 | 2006-12-27 | Glaxo Group Ltd | Compuestos derivados de benzamida como inhibidores del transportador de glicina |
| GB0428232D0 (en) | 2004-12-23 | 2005-01-26 | Glaxo Group Ltd | Compounds |
| WO2006067414A2 (en) | 2004-12-23 | 2006-06-29 | Glaxo Group Limited | Glycine transport inhibitors |
| PE20061156A1 (es) | 2004-12-23 | 2006-12-16 | Glaxo Group Ltd | Derivados de benzamida como agentes inhibidores del transportador de glicina |
| US7880002B2 (en) | 2004-12-29 | 2011-02-01 | Millennium Pharmaceuticals, Inc. | Substituted piperazinyl-pyrrolidine compounds useful as chemokine receptor antagonists |
| US7635698B2 (en) | 2004-12-29 | 2009-12-22 | Millennium Pharmaceuticals, Inc. | Compounds useful as chemokine receptor antagonists |
| ATE472327T1 (de) * | 2005-01-07 | 2010-07-15 | Hoffmann La Roche | Ä4-(heteroaryl)piperazin-1-ylü-(2,5-substituier e phenyl)methanon-derivate als glycin-transporter 1 (glyt-1) hemmer zur behandlung von neurologischen und neuropsychiatrischen erkrankungen |
| EP1851203A2 (en) | 2005-02-08 | 2007-11-07 | Merck & Co., Inc. | Inhibitors of checkpoint kinases |
| EP1866276A1 (en) | 2005-03-21 | 2007-12-19 | Celera Genomics | Alpha ketoamide compounds as cysteine protease inhibitors |
| DE102005014936A1 (de) | 2005-03-24 | 2006-12-14 | Abbott Gmbh & Co. Kg | Substituierte Oxindol-Derivate, diese enthaltende Arzneimittel und deren Verwendung |
| JP5140577B2 (ja) | 2005-03-31 | 2013-02-06 | タケダ カリフォルニア インコーポレイテッド | ヒドロキシステロイドデヒドロゲナーゼ阻害剤 |
| GB0510140D0 (en) | 2005-05-18 | 2005-06-22 | Addex Pharmaceuticals Sa | Novel compounds B2 |
| GB0510139D0 (en) | 2005-05-18 | 2005-06-22 | Addex Pharmaceuticals Sa | Novel compounds B1 |
| US20070021433A1 (en) | 2005-06-03 | 2007-01-25 | Jian-Qiang Fan | Pharmacological chaperones for treating obesity |
| CA2610196A1 (en) | 2005-06-09 | 2006-12-14 | Merck Frosst Canada Ltd. | Azacyclohexane derivatives as inhibitors of stearoyl-coenzyme a delta-9 desaturase |
| EP1893577A1 (en) | 2005-06-13 | 2008-03-05 | Theravance, Inc. | Biphenyl compounds useful as muscarinic receptor antagonists |
| US7408066B2 (en) | 2005-06-20 | 2008-08-05 | Schering Corproation | Carbon-linked substituted piperidines and derivatives thereof useful as histamine H3 antagonists |
| ATE450526T1 (de) | 2005-06-20 | 2009-12-15 | Schering Corp | Als antagonisten von histamin h3 geeignete piperidinderivate |
| JP2009506987A (ja) | 2005-08-02 | 2009-02-19 | ニューロゲン コーポレイション | ジピペラジニルケトンおよび関連する類似体 |
| EP1942733B1 (en) * | 2005-09-29 | 2012-03-21 | Merck Sharp & Dohme Corp. | Radiolabeled glycine transporter inhibitors |
| CN101282952A (zh) * | 2005-10-06 | 2008-10-08 | 塞诺菲-安万特股份有限公司 | 环状n-[1,3,4]-噻二唑-2-基-苯磺酰胺，其制备方法以及其作为药物的应用 |
| DE102005049954A1 (de) | 2005-10-19 | 2007-05-31 | Sanofi-Aventis Deutschland Gmbh | Triazolopyridin-derivate als Inhibitoren von Lipasen und Phospholipasen |
| WO2007057742A2 (en) | 2005-11-18 | 2007-05-24 | Pfizer Products Inc. | Novel piperazinone derivatives |
| EP1959947A2 (en) | 2005-12-15 | 2008-08-27 | Cytokinetics, Inc. | Certain chemical entities, compositions and methods |
| CA2634250A1 (en) | 2005-12-21 | 2007-07-05 | Schering Corporation | Phenoxypiperidines and analogs thereof useful as histamine h3 antagonists |
| CA2634847A1 (en) | 2005-12-21 | 2007-07-05 | Schering Corporation | Substituted aniline derivatives useful as histamine h3 antagonists |
| US20070161578A1 (en) | 2005-12-21 | 2007-07-12 | Hwa Joyce J | Treatment of nonalcoholic fatty liver disease using cholesterol lowering agents and/or H3 receptor antagonist/inverse agonist |
| PE20071162A1 (es) | 2005-12-21 | 2007-11-30 | Schering Corp | Combinacion de un antagonista/agonista inverso de h3 y un supresor del apetito |
| NZ569630A (en) | 2006-01-06 | 2011-09-30 | Sepracor Inc | Cycloalkylamines as monoamine reuptake inhibitors |
| GB0600427D0 (en) | 2006-01-10 | 2006-02-15 | Glaxo Group Ltd | Compounds |
| CN101421269A (zh) | 2006-01-13 | 2009-04-29 | 环状药物公司 | 酪氨酸激酶抑制剂及其用途 |
| WO2007087220A2 (en) | 2006-01-25 | 2007-08-02 | The Trustees Of Columbia University In The City Of New York | The total synthesis of ecteinascidin 743 and derivatives thereof |
| AR059355A1 (es) | 2006-02-07 | 2008-03-26 | Wyeth Corp | Inhibidores de 11-beta hsd1 |
| AU2007213734A1 (en) | 2006-02-10 | 2007-08-16 | Janssen Pharmaceutica N.V. | Piperidine derivatives as CXCR3 receptor antagonists |
| RU2318818C1 (ru) | 2006-04-12 | 2008-03-10 | Общество С Ограниченной Ответственностью "Исследовательский Институт Химического Разнообразия" | Азагетероциклы, комбинаторная библиотека, фокусированная библиотека, фармацевтическая композиция и способ получения (варианты) |
| EP2009011A1 (en) | 2006-04-14 | 2008-12-31 | Takeda Pharmaceutical Company Limited | Nitrogen-containing heterocyclic compound |
| US8017612B2 (en) | 2006-04-18 | 2011-09-13 | Japan Tobacco Inc. | Piperazine compound and use thereof as a HCV polymerase inhibitor |
| MX2008014353A (es) | 2006-05-09 | 2008-11-24 | Merck & Co Inc | Antagonistas de los receptores del peptido relacionado con el gen de calcitonina (cgrp) monociclicos sustituidos. |
| TW200808818A (en) | 2006-05-26 | 2008-02-16 | Shionogi & Co | Glycopeptide antibiotic derivatives |
| WO2007139150A1 (ja) | 2006-05-30 | 2007-12-06 | The University Of Tokushima | ＴＮＦα阻害物質を含有してなる抗インフルエンザウイルス剤 |
| MX2008015696A (es) | 2006-06-09 | 2009-02-10 | Icos Corp | Acidos fenil aceticos sustituidos como antagonistas de dp-2. |
| GB0612420D0 (en) | 2006-06-22 | 2006-08-02 | Glaxo Group Ltd | Compounds |
| GB0612416D0 (en) | 2006-06-22 | 2006-08-02 | Glaxo Group Ltd | Compounds |
| GB0612425D0 (en) | 2006-06-22 | 2006-08-02 | Glaxo Group Ltd | Compounds |
| GB0612435D0 (en) | 2006-06-22 | 2006-08-02 | Glaxo Group Ltd | Compounds |
| GB0612437D0 (en) | 2006-06-22 | 2006-08-02 | Glaxo Group Ltd | Compounds |
| KR101086589B1 (ko) | 2006-06-28 | 2011-11-23 | 암젠 인크 | 글리신 수송자-1 억제제 |
| UA94615C2 (uk) * | 2006-06-28 | 2011-05-25 | Амген Інк. | Інгібітори транспортера-1 гліцину |
| AU2007263809B2 (en) * | 2006-06-29 | 2013-07-18 | F. Hoffmann-La Roche Ag | Tetrazole-substituted arylamides |
| JP2008013527A (ja) | 2006-07-10 | 2008-01-24 | Sankyo Co Ltd | チエノ［３，２−ｄ］ピリミジン−２，４−ジアミン誘導体 |
| DE102006033114A1 (de) | 2006-07-18 | 2008-01-24 | Grünenthal GmbH | Spirocyclische Azaindol-Derivate |
| EP2066318B1 (en) | 2006-09-21 | 2010-05-12 | F. Hoffmann-Roche AG | Oxindole derivatives as anticancer agents |
| GB0621607D0 (en) | 2006-10-31 | 2006-12-06 | Chroma Therapeutics Ltd | Inhibitors of c-Met |
| JP2010509328A (ja) | 2006-11-08 | 2010-03-25 | シェーリング コーポレイション | プロテインキナーゼの阻害剤としてのイミダゾピラジン |
| ES2367455T3 (es) * | 2006-11-09 | 2011-11-03 | F. Hoffmann-La Roche Ag | Arilamidas sustituidas por tiazol u oxazol. |
| WO2008061109A2 (en) | 2006-11-15 | 2008-05-22 | Forest Laboratories Holdings Limited | Indazole derivatives useful as melanin concentrating receptor ligands |
| KR20080045537A (ko) | 2006-11-20 | 2008-05-23 | 에스케이케미칼주식회사 | 피리딘 화합물을 포함하는 간염 치료 및 예방 또는 간 보호효능을 갖는 약제 조성물 |
| EP2123637A4 (en) | 2006-11-30 | 2011-12-21 | Tokyo Inst Tech | NEW CURCUMIN DERIVATIVES |
| WO2008073452A1 (en) | 2006-12-11 | 2008-06-19 | Reviva Pharmaceuticals, Inc. | Compositions, synthesis, and methods of using indanone based cholinesterase inhibitors |
| DE102006060598A1 (de) | 2006-12-21 | 2008-06-26 | Merck Patent Gmbh | Tetrahydrobenzoisoxazole |
| US7737149B2 (en) | 2006-12-21 | 2010-06-15 | Astrazeneca Ab | N-[5-[2-(3,5-dimethoxyphenyl)ethyl]-2H-pyrazol-3-yl]-4-(3,5-dimethylpiperazin-1-yl)benzamide and salts thereof |
| US20080186971A1 (en) | 2007-02-02 | 2008-08-07 | Tarari, Inc. | Systems and methods for processing access control lists (acls) in network switches using regular expression matching logic |
| EP2144890A1 (en) | 2007-02-07 | 2010-01-20 | Wyeth | Method for preparing halogenated amines |
| WO2008106479A2 (en) | 2007-02-27 | 2008-09-04 | University Of South Florida | Poly(1,4-piperazin-2-ones) as rod-like protein- protein interaction inhibitors and their production |
| AU2008225753A1 (en) | 2007-03-13 | 2008-09-18 | Proximagen Limited | Tricyclic isoquinoline derivatives for treatment of obesity |
| JP5550352B2 (ja) | 2007-03-15 | 2014-07-16 | ノバルティス アーゲー | 有機化合物およびその使用 |
| CA2683557C (en) | 2007-04-09 | 2016-10-18 | Methylgene Inc. | Inhibitors of histone deacetylase |
| JP2008266236A (ja) | 2007-04-23 | 2008-11-06 | Kyorin Pharmaceut Co Ltd | 環状アミン誘導体又はその塩 |
| GB0709031D0 (en) | 2007-05-10 | 2007-06-20 | Sareum Ltd | Pharmaceutical compounds |
| EP2155689B1 (en) | 2007-05-31 | 2015-07-08 | Boehringer Ingelheim International GmbH | Ccr2 receptor antagonists and uses thereof |
| JP2010208945A (ja) | 2007-06-01 | 2010-09-24 | Mitsubishi Tanabe Pharma Corp | 複素環化合物 |
| US20100184996A1 (en) | 2007-06-20 | 2010-07-22 | Glaxo Group Limited | Process of amide formation |
| WO2008157844A1 (en) * | 2007-06-21 | 2008-12-24 | Forest Laboratories Holdings Limited | Novel piperazine derivatives as inhibitors of stearoyl-coa desaturase |
| CN101796032A (zh) | 2007-06-28 | 2010-08-04 | 英特维特国际股份有限公司 | 作为cb1拮抗剂的取代哌嗪 |
| EP2170846A2 (en) | 2007-06-28 | 2010-04-07 | Intervet International BV | Substituted piperazines as cb1 antagonists |
| WO2009005671A2 (en) | 2007-06-28 | 2009-01-08 | Schering Corporation | Substituted piperazines as cb1 antagonists |
| TW200911808A (en) | 2007-07-23 | 2009-03-16 | Astrazeneca Ab | Novel compounds |
| JP5160827B2 (ja) | 2007-07-25 | 2013-03-13 | 塩野義製薬株式会社 | グリコペプチド抗生物質誘導体 |
| JP5736098B2 (ja) | 2007-08-21 | 2015-06-17 | アッヴィ・インコーポレイテッド | 中枢神経系障害を治療するための医薬組成物 |
| US9909146B2 (en) | 2008-07-04 | 2018-03-06 | Scientist Of Fortune S.A. | Production of alkenes by enzymatic decarboxylation of 3-hydroxyalkanoic acids |
| JP5813101B2 (ja) | 2010-06-04 | 2015-11-17 | アルバニー モレキュラー リサーチ， インコーポレイテッド | グリシントランスポーター−１阻害剤、その作製方法および使用方法 |
-
2011
- 2011-06-02 JP JP2013513348A patent/JP5813101B2/ja not_active Expired - Fee Related
- 2011-06-02 CA CA2801074A patent/CA2801074A1/en not_active Abandoned
- 2011-06-02 US US13/151,992 patent/US9045445B2/en active Active
- 2011-06-02 NZ NZ604035A patent/NZ604035A/en not_active IP Right Cessation
- 2011-06-02 AU AU2011261375A patent/AU2011261375B2/en not_active Expired - Fee Related
- 2011-06-02 SG SG2013000047A patent/SG186885A1/en unknown
- 2011-06-02 KR KR1020137000117A patent/KR20130087002A/ko not_active Abandoned
- 2011-06-02 EP EP11790414.4A patent/EP2575815A4/en not_active Withdrawn
- 2011-06-02 CN CN201180038081.9A patent/CN103096893B/zh active Active
- 2011-06-02 WO PCT/US2011/038939 patent/WO2011153359A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013530957A5 (cg-RX-API-DMAC7.html) | ||
| RU2347777C2 (ru) | Двойные агонисты nk1/nk3 для лечения шизофрении | |
| RU2017101829A (ru) | Пиразоловые соединения в качестве модуляторов fshr и пути их применения | |
| RU2006107653A (ru) | Связующее вспомогательное вещество и приготовленная на его основе таблетка в форме капли | |
| AU2019301628A1 (en) | Pyridine carboxamide compounds for inhibiting NaV1.8 | |
| JP2015514073A5 (cg-RX-API-DMAC7.html) | ||
| JP2017511794A5 (cg-RX-API-DMAC7.html) | ||
| JP2017530185A5 (cg-RX-API-DMAC7.html) | ||
| RU2005101406A (ru) | Производные пиримидинсульфонамида в качестве модуляторов рецепторов хемокинов | |
| JP2005536475A5 (cg-RX-API-DMAC7.html) | ||
| BR0317645A (pt) | Composto ou um sal deste, composição farmacêutica, uso de um composto, e, método de tratamento e/ou profilaxia de uma doença inflamatória e/ou alérgica ou deterioração cognitiva em um mamìfero | |
| JP2009513703A5 (cg-RX-API-DMAC7.html) | ||
| RU2017116197A (ru) | 2-амино-3,5-дифтор-3,6-диметил-6-фенил-3,4,5,6-тетрагидропиридины как ингибиторы васе1 для лечения болезни альцгеймера | |
| IL264982B (en) | (hetero)aryl cyclopropylamine compounds as lsd1 inhibitors | |
| RU2017116196A (ru) | 2-амино-6-(дифторметил)-5,5-дифтор-6-фенил-3,4,5,6-тетрагидропиридины как ингибиторы васе1 | |
| RU2016141646A (ru) | Ингибиторы trka киназы, основанные на них композиции и способы | |
| EA031061B1 (ru) | Соединения и композиции в качестве ингибиторов киназ | |
| JP2004502670A5 (cg-RX-API-DMAC7.html) | ||
| RU2014106611A (ru) | Производные гетероциклических амидов в качестве антагонистов р2х7 рецептора | |
| RU2004126936A (ru) | Производные хинолина в качестве антагонистов npv | |
| RU2009103307A (ru) | ПРОИЗВОДНЫЕ ИМИДАЗО[1, 2-a]ПИРИДИН-2-КАРБОКСАМИДОВ, ИХ ПОЛУЧЕНИЕ И ПРИМЕНЕНИЕ В ТЕРАПИИ | |
| JP2018522847A5 (cg-RX-API-DMAC7.html) | ||
| RU2019136279A (ru) | C5 -Анилинохиназолиновые соединения и их использование в лечении рака | |
| RU2004102397A (ru) | Применение антагонистов рецептора nk-1 для лечения черепно-мозговой и спинномозговой травмы или повреждения нервной ткани | |
| RU2006101541A (ru) | Производные пиперазина и способ их применения |